325 related articles for article (PubMed ID: 33450188)
1. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response.
Golebski K; Layhadi JA; Sahiner U; Steveling-Klein EH; Lenormand MM; Li RCY; Bal SM; Heesters BA; Vilà-Nadal G; Hunewald O; Montamat G; He FQ; Ollert M; Fedina O; Lao-Araya M; Vijverberg SJH; Maitland-van der Zee AH; van Drunen CM; Fokkens WJ; Durham SR; Spits H; Shamji MH
Immunity; 2021 Feb; 54(2):291-307.e7. PubMed ID: 33450188
[TBL] [Abstract][Full Text] [Related]
2. Role of IL-35 in sublingual allergen immunotherapy.
Shamji MH; Layhadi JA; Achkova D; Kouser L; Perera-Webb A; Couto-Francisco NC; Parkin RV; Matsuoka T; Scadding G; Ashton-Rickardt PG; Durham SR
J Allergy Clin Immunol; 2019 Mar; 143(3):1131-1142.e4. PubMed ID: 30053528
[TBL] [Abstract][Full Text] [Related]
3. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
4. Birch pollen-specific subcutaneous immunotherapy reduces ILC2 frequency but does not suppress IL-33 in mice.
van Rijt LS; Logiantara A; Canbaz D; van Ree R
Clin Exp Allergy; 2018 Nov; 48(11):1402-1411. PubMed ID: 30126007
[TBL] [Abstract][Full Text] [Related]
5. Relevance of a 5-grass sublingual tablet for immunotherapy of patients with grass pollen allergy in North America.
Moingeon P; Cox L
Expert Rev Clin Immunol; 2016 Jun; 12(6):617-23. PubMed ID: 26813047
[TBL] [Abstract][Full Text] [Related]
6. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
[TBL] [Abstract][Full Text] [Related]
7. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Kopp M; Liebke C; Lange J; Wahn U; Niggemann B
Int Arch Allergy Immunol; 2005 Feb; 136(2):134-41. PubMed ID: 15650310
[TBL] [Abstract][Full Text] [Related]
8. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.
Francis JN; Till SJ; Durham SR
J Allergy Clin Immunol; 2003 Jun; 111(6):1255-61. PubMed ID: 12789226
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical efficacy of grass-pollen immunotherapy.
Durham SR; Walker SM; Varga EM; Jacobson MR; O'Brien F; Noble W; Till SJ; Hamid QA; Nouri-Aria KT
N Engl J Med; 1999 Aug; 341(7):468-75. PubMed ID: 10441602
[TBL] [Abstract][Full Text] [Related]
10. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.
Durham SR; Ying S; Varney VA; Jacobson MR; Sudderick RM; Mackay IS; Kay AB; Hamid QA
J Allergy Clin Immunol; 1996 Jun; 97(6):1356-65. PubMed ID: 8648033
[TBL] [Abstract][Full Text] [Related]
11. Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy.
Eljaszewicz A; Ruchti F; Radzikowska U; Globinska A; Boonpiyathad T; Gschwend A; Morita H; Helbling A; Arasi S; Kahlert H; Berek N; Nandy A; Akdis M; Willers C; Moniuszko M; Akdis CA; Sokolowska M
J Allergy Clin Immunol; 2021 May; 147(5):1865-1877. PubMed ID: 33039478
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
[TBL] [Abstract][Full Text] [Related]
13. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
14. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
Nouri-Aria KT; Wachholz PA; Francis JN; Jacobson MR; Walker SM; Wilcock LK; Staple SQ; Aalberse RC; Till SJ; Durham SR
J Immunol; 2004 Mar; 172(5):3252-9. PubMed ID: 14978133
[TBL] [Abstract][Full Text] [Related]
15. Intradermal grass pollen immunotherapy increases T
Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
[TBL] [Abstract][Full Text] [Related]
17. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production.
Burastero SE; Mistrello G; Falagiani P; Paolucci C; Breda D; Roncarolo D; Zanotta S; Monasterolo G; Rossi RE
Ann Allergy Asthma Immunol; 2008 Apr; 100(4):343-50. PubMed ID: 18450120
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
Malling HJ; Lund L; Ipsen H; Poulsen L
J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
[TBL] [Abstract][Full Text] [Related]
19. Allergen Immunotherapy for a Teenager with Seasonal Allergic Rhinitis Due to Grass Pollen: Subcutaneous or Sublingual Route?
Nelson HS; Durham SR
J Allergy Clin Immunol Pract; 2017; 5(1):52-57. PubMed ID: 28065341
[No Abstract] [Full Text] [Related]
20. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
